Scientists hunt for biomarkers to personalize endometrial cancer immunotherapy
NCT ID NCT07374809
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study will analyze tumor samples from 50 women with advanced or recurrent endometrial cancer to find biological markers that predict whether immunotherapy will work. Researchers will examine the tumor's DNA, epigenetics, and surrounding environment. The goal is to better understand why some patients respond to treatment and others do not, paving the way for more personalized care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DMMR CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Istituto Europeo di Oncologa
Milan, Lombardy, 20141, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Radiotherapy revolution: could 5 sessions replace 25 for endometrial cancer?
- New combo aims to spare surgery for certain cancer patients
- New cocktail aims to shrink rectal tumors before surgery
- Virus therapy fails to advance in colorectal cancer trial
- New hope for Hard-to-Treat cancers: experimental drug enters human trials
- Triple threat: radiotherapy, chemo, and immunotherapy take on spread rectal cancer